【原著・著書・総説】

1.  Ozaki Y, Yoshino Y, Yamazaki K, Ochi S, Iga JI, Nagai M, Nomoto M, Ueno SI.
DRD2 methylation to differentiate dementia with Lewy bodies from Parkinson’s disease.
Acta Neurol Scand. 2020;141(2):177-182.　doi: 10.1111/ane.13186.

2.  Miyaue N, Yamanishi Y, Tada S, Ando R, Yabe H, Nagai M.
Acromioclavicular joint arthritis as the first manifestation of Austrian syndrome.
J Infect Chemother. 2020;26(1):124-127.　doi: 10.1016/j.jiac.2019.06.009.

3.  Miyaue N, Yabe H, Nagai M.
Serum growth differentiation factor 15, but not lactate, is elevated in patients with Parkinson’s disease.
J Neurol Sci. 2020;409:116616.　doi: 10.1016/j.jns.2019.116616.

4.  Iwaki H, Ando R, Tada S, Nishikawa N, Tsujii T, Yamanishi Y, Miyaue N, Yabe H, Nagai M, Nomoto M.
A double-blind, randomized controlled trial of duloxetine for pain in Parkinson’s disease.
J Neurol Sci. 2020;414:116833.　doi: 10.1016/j.jns.2020.116833.

5.  Miyaue N, Yabe H, Nagai M, Nomoto M.
Abnormal upper gastrointestinal structures underlying levodopa malabsorption.
J Neurol Sci. 2020;414:116855.　doi: 10.1016/j.jns.2020.116855.

6.  Nagai M, Kubo M, Ando R, Ikeda M, Iwamoto H, Takeda Y, Nomoto M.
Comparative examination of levodopa pharmacokinetics during simultaneous administration with lactoferrin in healthy subjects and the relationship between lipids and COMT inhibitory activity in vitro.
Nutr Neurosci. 2022;25(3):462-471.　doi: 10.1080/1028415X.2020.1760532.

7.  Miyaue N, Yabe H, Nagai M.
Serum growth differentiation factor 15 levels and clinical manifestations in patients with thiamine deficiency.
Neurol Clin Neurosci. 2020;8(5):245-250.　doi: 10.1111/ncn3.12390.

8.  Miyaue N, Yabe H, Yamanishi Y, Tada S, Ando R, Nagai M.
Relapse of neuromyelitis optica with occipital neuralgia and elevated CSF neopterin.
Neurol Clin Neurosci. 2020;8(4):209-211.　doi: 10.1111/ncn3.12393.

9.  Kodama D, Tanaka M, Matsuzaki T, Izumo K, Nakano N, Matsuura E, Saito M, Nagai M, Horiuchi M, Utsunomiya A, Takashima H, Kubota R, Izumo S.
Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviralloads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.
PLOS Negl Trop Dis. 2020;14(7):e0008361.　doi: 10.1371/journal.pntd.0008361.

10. Miyaue N, Yabe H, Nagai M, Nomoto M.
Gastrointestinal surgical procedures affect levodopa pharmacokinetics in Parkinson’s disease.
Parkinsonism Relat Disord. 2020;76:29-31.　doi: 10.1016/j.parkreldis.2020.05.40.

11. Miyaue N, Yabe H, Nagai M, Nomoto M.
Percutaneous transesophageal gastro‐tubing as an alternative procedure of levodopa administration in Parkinson’s disease.
Mov Disord Clin Pract. 2020;7(6):730-732.　doi: 10.1002/mdc3.13014.

12. Tada S, Nomoto M, Yamanishi Y, Miyaue N, Ando R, Yabe H, Nagai M.
The marked decrease in cardiac MIBG-uptake correlates with the severity of sleep disturbance in patients with Parkinson’s disease.
Sleep Biol Rhythm. 2020;18:131-136.　doi: 10.1007/s41105-020-00253-1.

13. Okamoto K, Motoki T, Saito I, Urate R, Aibara K, Jogamoto T, Fukuda M, Wakamoto H, Maniwa S, Kondo Y, Toda Y, Goji A, Mori T, Soga T, Konishi Y, Nagai S, Takami Y, Tokorodani C, Nishiuchi R, Usui D, Ando R, Tada S, Yamanishi Y, Nagai M, Arakawa R, Saito K, Nishio H, Ishii E, Eguchi M.
Survey of patients with spinal muscular atrophy on the island of Shikoku, Japan.
Brain Dev. 2020;42(8):594-602.　doi: 10.1016/j.braindev.2020.05.004.

14. Miyaue N, Yabe H, Yamanishi Y, Tada S, Ando R, Nagai M.
Three cases of rheumatoid meningitis with elevated CSF neopterin levels.
J Neuroimmunol. 2020;348:577396.　doi: 10.1016/j.jneuroim.2020.577396.

15. Jogamoto T, Utsunomiya R, Sato A, Kihara N, Choudhury ME, Miyanishi K, Kubo M, Nagai M, Nomoto M, Yano H, Shimizu YI, Fukuda M, Ishii E, Eguchi M, Junya Tanaka J.
Lister hooded rats as a novel animal model of attention-deficit/hyperactivity disorder.
Neurochem Int. 2020;141:104857.　doi: 10.1016/j.neuint.2020.104857.

16. Miyaue N, Yabe H.
Hemifacial anhidrosis in neuromyelitis optica spectrum disorder.
Neurol Clin Neurosci. 2020;8(2):107-108.　doi: 10.1111/ncn3.12363.

17. 山西祐輝,永井将弘
LCIG療法におけるレボドパ血中濃度モニタリング
愛媛医学. 2020; 39(1):5-8.

18. 永井将弘,服部信孝
新規パーキンソン病治療薬ラサギリンメシル酸塩（アジレクト®錠）の薬理学的特徴と臨床効果
日本薬理学会. 2020; 155(3):187-194.

 

【学会・研究会】

1.  第61回日本神経学会学術大会,岡山＆WEB,8.31-9.2,2020.
・山西祐輝
LCIG療法中におけるチューブ先端位置とレボドパ血中濃度の検討

・永井将弘
パーキンソン病の痛みに対するデュロキセチン二重盲検ランダム化比較試験

・安藤利奈
Japan Registry of Clinical Trialsのデータを用いた脳神経内科関連疾患の分析

2.  第38回日本神経治療学会学術集会,東京＆WEB,10.28-30,2020.
・吉田暉,細川裕子,山西祐輝,多田聡,安藤利奈,永井将弘
ステロイドミオパチーに対する分岐鎖アミノ酸の有用性（症例報告）

3.  第41回日本臨床薬理学会学術総会,福岡＆WEB,12.3-12.5,2020.
・永井将弘
パーキンソン病に対する抗αシヌクレイン抗体療法

・安藤利奈
進行性核上性麻痺に対する抗タウ抗体製剤

4.  第108回日本神経学会中国・四国地方会,WEB(香川),12.5,2020.
・桑垣詩織,多田聡,吉田暉,細川裕子,山西祐輝,安藤利奈,永井将弘
PEG-Jチューブ交換直後にレボドパ血中濃度測定を行ったLCIG療法導入パーキンソン病の一例